Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U87 CAR-T in Advanced Solid Tumors
NCT05605197Phase 1Recruiting
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of U87 autologous CAR T-cell in solid tumor (advanced stage) and pancreatic cancer (PC), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoint: Incidence of Adverse events after U87 CAR-T cells infusion at 28 days. Started Oct 2022; status: recruiting.
02
Drugs
U87 autologous CAR T-cell
03
Conditions
solid tumor (advanced stage)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05605197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605197.